The Neoadjuvant Treatment of Rectal Cancer: A Review

Current Oncology Reports

Volumn 17, Issue 3, 2015, Pages

  Nussbaum, Nathan ^a   Altomare, Ivy ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Chemoradiotherapy; Neoadjuvant; Rectal cancer; Review; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); PROCEDURES; RECTAL NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; NEOADJUVANT THERAPY; RECTAL NEOPLASMS;

EID: 84923677277     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0434-9     Document Type: Review

References (50)

1. Siegel R et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.
3. Kosinski L et al. Shifting concepts in rectal cancer management: a review of contemporary primary rectal cancer treatment strategies. CA Cancer J Clin. 2012;62(3):173–202.
4. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following “curative surgery” for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer. 1974;34(4):1278–92.
5. Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma. N Engl J Med. 1985;312(23):1465–72.
6. Douglass Jr HO et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986;315(20):1294–5.
7. Krook JE et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.
8. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA, 1990. 264(11): p. 1444–50
9. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med. 1997;336(14):980–7.
10. Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.
11. Sauer R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.
12. Sauer R et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.
13. Hofheinz RD et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579–88.
14. Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
15. Martin LK, Bekaii-Saab T. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. J Natl Compr Canc Netw. 2013;11(3):298–307. quiz 307.
16. Rodel C et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003;21(16):3098–104.
17. Aschele C et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol. 2005;16(7):1140–6.
18. Freyer G et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97–03 phase I trial. J Clin Oncol. 2001;19(9):2433–8.
19. Carraro S et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys. 2002;54(2):397–402.
20. Aschele C et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.
21. Gerard JP et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.
22. Roh MS et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011;29(15):abstr 3503.
23. Rodel C et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.
24. Schmoll H-J et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. J Clin Oncol. 2014;32(5s):abstr 3501.
25. Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.
26. Douillard JY et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.
27. Bonner JA et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.
28. Eisterer WM et al. Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03. J Clin Oncol. 2009;27(15s):abstr 4109.
29. Bertolini F et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73(2):466–72.
30. Helbling D et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol. 2013;24(3):718–25.
31. Landry JC et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 2013;119(8):1521–7.
32. Spigel DR et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer. 2012;11(1):45–52.
33. Kennecke H et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer. 2012;48(1):37–45.
34. Dipetrillo T et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):124–9.
35. Czito BG et al. The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study. J Clin Oncol. 2014;32(5s):abstr 3634.
36. Von Moos R, Dieter Koeberle SS, Stefanie H, Winterhalder RC, Arnaud R, Gyorgy B, et al. Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08. J Clin Oncol. 2014;32(5s):abstr 3531.
37. Fernandez-Martos C et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–65.
38. Chua YJ et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241–8.
39. Halim; IIA et al. Induction chemotherapy followed by concomitant chemoradiotherapy in locally advanced rectal carcinoma. J Clin Oncol. 2014;32:abstr e14546.
40. Marechal R et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23(6):1525–30.
41. Dewdney A et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–7.
42. Sclafani F et al. Panex: a pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC). J Clin Oncol. 2014;32(5s):abstr 3575.
43. Wolff HA et al. Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol. 2013;108(1):48–54.
44. Velenik V et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. 2010;36(3):244–50.
45. Ishii Y et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36(11):1061–5.
46. Uehara K et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43(10):964–71.
47. Koike J et al. Neoadjuvant mFOLFOX6 for stage II/III rectal cancer patients with a T3/T4 tumor. J Clin Oncol. 2014;32(5s):abstr 3554.
48. Cercek A et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. J Clin Oncol. 2010;28(15s):abstr 3649.
49. Schrag D et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32(6):513–8.
50. Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery. [cited 2014 9/14/2014]; Available from: http://clinicaltrials.gov/show/NCT01515787.